Literature DB >> 18249301

Evolving trends in nonalcoholic fatty liver disease.

Jorge-Shmuel Delgado1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common etiologies of chronic liver disease worldwide. NALFD encompasses a continuum of histological findings ranging from steatosis alone, to nonalcoholic steatohepatitis (NASH) with steatosis, inflammation, hepatocyte ballooning, fibrosis and eventually liver cirrhosis. The pathogenesis of NAFLD might be related to a deregulated cross-talk between liver and visceral adipose tissue, originating an impairment of normal insulin signaling. A better comprehension of the immunologic and metabolic roles of adipose tissue in modulating inflammatory pathways will enhance our understanding of the molecular mechanisms leading to progression of fatty liver disease. These insights, moreover, will suggest new strategies to improve insulin sensitivity and reduce obesity-associated morbidities and mortality.

Entities:  

Mesh:

Year:  2008        PMID: 18249301     DOI: 10.1016/j.ejim.2007.02.034

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  13 in total

Review 1.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

Review 2.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

3.  Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.

Authors:  Ming Tong; Alexander Neusner; Lisa Longato; Margot Lawton; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

4.  Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Matthew D Merrell; Rhiannon N Hardwick; Amy M Bataille; Sarah N Campion; Daniel W Ferreira; Stavra A Xanthakos; Jose E Manautou; H Hesham A-Kader; Robert P Erickson; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2015-03-18       Impact factor: 3.922

5.  Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice.

Authors:  Jamil A Haque; Ryan S McMahan; Jean S Campbell; Masami Shimizu-Albergine; Angela M Wilson; Dianne Botta; Theo K Bammler; Richard P Beyer; Thomas J Montine; Matthew M Yeh; Terrance J Kavanagh; Nelson Fausto
Journal:  Lab Invest       Date:  2010-06-14       Impact factor: 5.662

6.  Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis.

Authors:  Wenqian Fang; Zhiyong Deng; Feriel Benadjaoud; Chongzhe Yang; Guo-Ping Shi
Journal:  Transl Res       Date:  2020-05-11       Impact factor: 7.012

Review 7.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

8.  Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis.

Authors:  Lascelles E Lyn-Cook; Margot Lawton; Ming Tong; Elizabeth Silbermann; Lisa Longato; Ping Jiao; Princess Mark; Jack R Wands; Haiyan Xu; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 9.  Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Alexander Neusner; Jennifer Chu; Margot Lawton
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.

Authors:  Suzanne M de la Monte; Ming Tong; Margot Lawton; Lisa Longato
Journal:  Mol Neurodegener       Date:  2009-12-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.